文献速递银屑病与炎症性皮肤病

司库奇尤单抗对比乌司奴单抗对中重度斑块状银屑病患者生活质量和症状的影响:CLEAR 52周研究分析

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
PubMed 文献 · J Am Acad Dermatol · 2017-10-21

该事后分析基于CLEAR试验,比较司库奇尤单抗与乌司奴单抗对中重度斑块状银屑病患者症状完全缓解和生活质量应答时间的影响。结果显示司库奇尤单抗组更多患者在16周和52周达到疼痛完全缓解,瘙痒和鳞屑完全缓解中位时间分别快4周和8周,DLQI应答快4周,52周累积获益更大。

要点

  • 司库奇尤单抗在16周和52周疼痛完全缓解率显著高于乌司奴单抗。
  • 瘙痒和鳞屑完全缓解中位时间分别较乌司奴单抗快4周和8周。
  • DLQI应答中位时间快4周,52周累积获益更大。

核心结论

  • 司库奇尤单抗较乌司奴单抗对中重度斑块状银屑病患者的生活质量和症状缓解带来更大且持续的获益。

研究设计与样本

  • CLEAR试验的事后分析,比较司库奇尤单抗与乌司奴单抗治疗中重度斑块状银屑病患者的症状完全缓解时间和DLQI应答时间,并采用曲线下面积分析评估52周累积获益。

主要发现

  • 司库奇尤单抗组在16周和52周达到疼痛完全缓解的患者显著更多(均P < .05)。
  • 司库奇尤单抗组瘙痒和鳞屑完全缓解的中位时间分别快4周和8周(P < .001)。
  • 司库奇尤单抗组DLQI应答的中位时间快4周(P < .0001)。
  • 司库奇尤单抗组52周累积获益更大(均P < .05)。

临床怎么用

  • 对于中重度斑块状银屑病,若希望更快缓解瘙痒、鳞屑和疼痛并改善生活质量,可优先考虑司库奇尤单抗。

局限性

  • 分析为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile. OBJECTIVE: To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis. METHODS: Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) score were compared between treatments on the basis of time to complete relief of symptoms and time to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index score, symptom relief, and DLQI response were evaluated by area under the curve analysis. RESULTS: Significantly more patients treated with secukinumab achieved complete relief of pain at weeks 16 and 52 (all P < .05). Complete relief of itching and scaling occurred significantly faster with secukinumab (median, 4 weeks faster for itching and 8 weeks faster for scaling [P < .001]). Response as measured by the DLQI was 4 weeks faster with secukinumab (P < .0001). Cumulative benefits were greater with secukinumab (all P < .05). LIMITATIONS: Analyses were post hoc. CONCLUSION: This patient-reported outcome analysis confirms greater and sustained benefits of secukinumab versus those of ustekinumab treatment on patients' lives.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Puig L, Augustin M, Blauvelt A, et al. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. J Am Acad Dermatol. 2017. PMID: 29066271. doi:10.1016/j.jaad.2017.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。